EC5026 not checked

EicOsis Human Health Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
6 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose…”In the company’s words, NCT06438471 on ClinicalTrials.gov
Tested for
Parkinson's Disease (PD), Chronic Kidney Disease, Spinal Cord Injuries, Neuropathic Pain, Degenerative Disc Disease, Spinal Stenosis, Spondylosis
Main trialPhase 1/2
“The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are: * Is EC5026 safe in adults with Parkinson's Disease? * What are the levels of EC5026 achieved after oral administration for 28 days? * What molecules or pathways does EC5026 target, and to what extent? In addition, although it is not one of the primary aims of the…”In the company’s words, NCT07142044 on ClinicalTrials.gov

Other drugs for Chronic Kidney Disease

All 79 drugs for Chronic Kidney Disease

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Dec 2026 Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)
Phase 1Recruiting 31 Dec 2026 Renal Impairment Study for Oral EC5026
Phase 1Recruiting Dec 2027 Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
Phase 1Completed 7 Jul 2020 Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects
Phase 1Completed 12 May 2021 Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects
Phase 1Completed 13 Mar 2024 Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow EC5026

Following is part of Solo: you see every change to EC5026 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in